Pila Pharma recently announced that the lack of weight loss in the company's preclinical obesity studies was likely due to low exposure rather than lack of efficacy. A new formulation appears to have hindered the uptake of the candidate XEN-D0501. BioStock contacted CEO Gustav Gram to discuss the latest analyses, the path forward towards a phase II clinical study, and the most important milestones for investors in 2026.
See the interview at biostock.se:
Pila Pharma on the preclinical results and the way forward
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/